108TiPEMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%.

Authors :: Sriuranpong, V
Altundag, O
Clingan, P
Rizvi, N
Frontera, O Aren
Sezer, A
Paydas, S
Shavdia, M
Bondarenko, I
Gladkov, O
Lee, S
Li, S
Snodgrass, P
Rietschel, P
Source :: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Publication Year :: 2018

Full Text Access

Tools